Ivermectin Disappoints in Mild COVID-19
email article COVID-19 patients treated in a randomized trial with the anti-parasitic drug ivermectin did no better than a placebo group, Colombian researchers said. Median time to recovery among mild COVID-19 patients in the ivermectin group was 10 days versus 12 days among those receiving placebo, and rates of symptom resolution at day 21 were about equal, reported Eduardo López-Medina, MD, of Centro de Estudios en Infectología Pediátrica, and colleagues, writing in But the trial was far from perfect. The initial primary outcome was time from randomization until worsening of sympt...